XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Licenses, Asset Acquisitions and Contingent Consideration (Tables)
 9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Schedule of IPR&D Expense
The Company recorded the following IPR&D expense on the condensed consolidated statements of operations (in thousands):
Three months ended September 30,Nine months ended September 30,
2021202020212020
GB004— 275 — 15,275 
Other preclinical programs15 — 60 2,805 
Total in process research and development$15 $275 $60 $18,080